Anifrolumab denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Anifrolumab on Medical-Necessity Grounds

Anifrolumab (Saphnelo) is a type I interferon receptor antagonist approved by the FDA for adults with moderate-to-severe systemic lupus erythematosus (SLE). Cigna's medical-necessity denials for this drug typically follow a pattern: the plan's coverage policy sets specific criteria — diagnosis confirmation, disease severity classification, prior treatment requirements, and prescriber specialty — and the submission either omitted documentation for one of those criteria or the reviewer concluded the record did not satisfy them. These denials are routinely overturned on appeal when the right documentation is assembled.

## Why This Denial Is Appealable

Anifrolumab is FDA-approved for this indication and is recognized by relevant specialty societies, including those representing rheumatology practice, as an appropriate treatment option for qualifying patients. A coverage denial does not mean the treatment is inappropriate for your patient — it means the plan's administrative criteria have not yet been satisfied on paper. That is a documentation problem, not a clinical one, and it is correctable.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Submit a written appeal with supporting documentation. For non-urgent cases the plan generally has 60 days to decide; urgent/expedited cases must be decided within 72 hours.
• External review: If the internal appeal is denied, you may request independent external review. Under ACA §2719, this right applies to most employer-sponsored and individual/small-group plans. You typically have four months from the denial date to request external review. An independent organization — not the insurer — makes the final binding decision. Expedited external review is available when waiting would seriously jeopardize health.

## Documentation to Gather

1. Confirmed SLE diagnosis — rheumatologist visit notes, ANA and specific antibody results, ACR/EULAR classification documentation. 2. Disease severity — SLEDAI or equivalent validated disease-activity scores recorded in the chart, organ-involvement documentation, flare history with dates. 3. Prior treatment history — a dated list of every prior immunosuppressant or standard-of-care agent tried, dose duration, and outcome (inadequate response, intolerance, or contraindication per treating physician judgment). 4. Prescriber medical-necessity letter — from the treating rheumatologist explaining why anifrolumab is appropriate for this patient now, referencing the applicable guideline organization (e.g., ACR) and how the patient's chart satisfies each criterion in Cigna's published coverage policy. 5. Cigna's current coverage policy — obtain the exact policy number and version from the denial letter, then pull the full text from Cigna's website. Map every listed criterion to a specific chart entry.

## Criteria-Mapping Structure

In your appeal letter, create a two-column table. Left column: copy each requirement verbatim from Cigna's coverage policy. Right column: cite the specific chart date and finding that satisfies it. Leave nothing assumed. If the policy requires documentation from a specialist, attach the relevant visit note. This structure forces the reviewer to address each criterion individually rather than issuing a blanket denial.